Canaccord analyst Kyle Mikson lowered the firm’s price target on Exact Sciences to $85 from $90 and keeps a Buy rating on the shares following the Q1 report. The analyst remains bullish, but cut the target to reflect a modestly more cautious setup going forward as recent commercial investments have yet to make a meaningful impact on revenue. Exact provided Q2 revenue guidance that was a touch lower than Street estimates and reaffirmed its 2024 guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- EXAS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- Exact Sciences Announces Board Member Retirement
- Exact Sciences CFO’s resume ‘impressive,’ says William Blair
- Exact Sciences Appoints Aaron Bloomer as New CFO